Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan:6:e2100437.
doi: 10.1200/PO.21.00437.

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Joanne Lundy  1   2   3   4 , Owen McKay  5 , Daniel Croagh  1   2   3 , Vinod Ganju  4   6
Affiliations
Review

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Joanne Lundy et al. JCO Precis Oncol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Joanne LundyPatents, Royalties, Other Intellectual Property: Patent pending for molecular diagnostic signature of pancreatic cancer (Inst) Daniel CroaghStock and Other Ownership Interests: Margin-ClearHonoraria: Boston ScientificSpeakers' Bureau: OncoSil (Inst)Patents, Royalties, Other Intellectual Property: Patent on molecular diagnostic signature for pancreatic cancer (Inst), Patent for the brachytherapy device for use at the operative site following resectionOther Relationship: Boston Scientific (Inst) Vinod GanjuHonoraria: Roche/Genentech, AstraZenecaNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
PET scan at baseline and after six cycles of carboplatin and nab-paclitaxel chemotherapy reveals excellent partial response to initial systemic therapy. Baseline PET scan including (A) MIP and (B) computed tomography fused axial views demonstrates pancreatic primary and extensive liver metastases. Follow-up (C) MIP and (D) fused axial views after six cycles of platinum-based chemotherapy with the addition of pembrolizumab from C4 demonstrate near-complete resolution of disease, with only a solitary remaining fluorodeoxyglucose-avid liver metastasis (arrow). MIP, maximum intensity projection; PET, positron emission tomography.
FIG 2.
FIG 2.
Response to olaparib after oligometastatic progression in liver. (A) PET scan and (B) MRI of liver after 5 months of maintenance pembrolizumab reveal progression in the sole remaining metastatic liver lesion. Olaparib was added, and 5 months later, a repeat (C) PET scan and (D) MRI demonstrate complete radiologic and metabolic response to therapy. MRI, magnetic resonance imaging PET, positron emission tomography.
See this image and copyright information in PMC

Comment in

References

    1. Sung H, Ferlay J, Siegel RL, et al. : Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021 - PubMed
    1. Wade TP, Halaby IA, Stapleton DR, et al. : Population-based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals, 1989–1994. Surgery 120:680-687, 1996 - PubMed
    1. Sohal DPS, Kennedy EB, Cinar P, et al. : Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol 38:3217-3230, 2020 - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. : Cancer statistics, 2021. CA Cancer J Clin 71:7-33, 2021 - PubMed
    1. Witkiewicz AK, McMillan EA, Balaji U, et al. : Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744, 2015 - PMC - PubMed